Dyspnea due to pulmonary hypertension and interstitial lung disease in scleroderma: Room for improvement in diagnosis and management

Journal of Rheumatology

Volumn 33, Issue 9, 2006, Pages 1723-1725

  Racz, Heather ^a   Mehta, Sanjay ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; EXERCISE TEST; FATIGUE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

DIAGNOSIS, DIFFERENTIAL; DYSPNEA; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; SCLERODERMA, SYSTEMIC;

EID: 33748541645     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Langevitz P, Alderdice CA, Aubrey M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;119:2-10.
3. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154-67.
4. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol 2005;11:40-6.
5. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33:269-74.
6. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
7. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
8. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
9. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
10. Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998;114:1623-9.
11. Kocheril SV, Appleton BE, Somers EC, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005;53:549-57.
12. Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y. New therapeutic strategies for systemic sclerosis - a critical analysis of the literature. Clin Dev Immunol 2005;12:165-73.
13. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
15. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
16. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
17. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32. Epub 2005 Dec 9.
18. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004;126 Suppl:7S-10S.
19. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
20. Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006;33:1789-801.
21. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.
22. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
23. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997;40:1229-36.
24. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:315-21.
25. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, duBois RM. Comparison of doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.